Related Experiment Video

Updated: Feb 16, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.0K

BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer

Hitomi Sumiyoshi Okuma1, Kan Yonemori2

  • 1Department of Breast and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.

Advances in Experimental Medicine and Biology
|December 29, 2017
PubMed

Insights

PARP inhibitors offer a promising new treatment for aggressive triple-negative breast cancer (TNBC) in patients with BRCA mutations. These inhibitors target DNA repair pathways, showing significant potential in clinical trials.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Breast cancer is a leading global cancer in women, with triple-negative breast cancer (TNBC) being the most aggressive subtype.
  • TNBC lacks hormone receptor and HER2 expression, resulting in limited therapeutic options.
  • BRCA mutations are found in approximately 5% of breast cancer patients, with a high co-occurrence (57.1%) in TNBC.

Purpose of the Study:

  • To explore the role of BRCA mutations in breast cancer, particularly TNBC.
  • To investigate the mechanism and therapeutic potential of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated breast cancers.
  • To discuss the clinical efficacy and challenges associated with PARP inhibitor therapy.

Main Methods:

  • Review of current research on BRCA mutations and their link to TNBC.
  • Analysis of the DNA repair pathways involving BRCA and PARP.
  • Examination of preclinical and clinical trial data for PARP inhibitors in BRCA-mutated breast cancer.

Main Results:

  • BRCA mutations impair DNA repair, creating synthetic lethality in cancer cells.
  • PARP inhibitors exploit this vulnerability, showing promising anti-cancer activity.
  • Ongoing phase III trials are evaluating the efficacy of PARP inhibitors in BRCA-mutated breast cancers.

Conclusions:

  • PARP inhibitors represent a targeted therapy with significant clinical potential for BRCA-mutated TNBC.
  • Understanding the interplay between BRCA, PARP, and DNA repair is crucial for advancing breast cancer treatment.
  • Further clinical evaluation is necessary to overcome barriers and optimize the use of PARP inhibitors.
Keywords:
BRCA mutationPARP inhibitorSynthetic lethalityTriple-negative breast cancer

More Related Videos

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.1K
Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System10:51

Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System

Published on: April 23, 2021

4.7K

Related Concept Videos

Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
64.7K
Bacterial RNA Polymerase00:43

Bacterial RNA Polymerase

Unlike eukaryotes, bacteria use a single RNA Polymerase (RNAP) to transcribe all genes. The different subunits of bacterial RNAPhave distinct functions. The multisubunit structure of the bacterial RNAP helps the enzyme to maintain catalytic function, facilitate assembly, interact with DNA and RNA, and self-regulate its activity.
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
32.9K
Translesion DNA Polymerases02:10

Translesion DNA Polymerases

Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
11.3K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
Eukaryotic RNA Polymerases00:58

Eukaryotic RNA Polymerases

RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
All three eukaryotic RNAPs require specific transcription factors, of which the...
27.2K
Mutations01:39

Mutations

Overview
94.7K